The active ingredient is identical
Both Ozempic and Wegovy contain semaglutide — a long-acting GLP-1 receptor agonist designed for once-weekly subcutaneous injection. The molecule, the manufacturer, and the mechanism of action are identical. What differs is the dose strength of the pen, the indication on the FDA label, and the clinical-trial program that supports each label.
Dosing differences
Ozempic titrates from 0.25 mg to a maximum of 2.0 mg weekly across roughly 12 weeks, per the FDA Ozempic prescribing information. Wegovy follows the same early titration but continues escalating to 2.4 mg weekly across 16+ weeks, per the FDA Wegovy label. The higher Wegovy dose is responsible for most of the difference in mean weight loss observed in clinical trials.
Trial efficacy
In STEP-1, semaglutide 2.4 mg (Wegovy) produced a mean total body weight loss of roughly 14.9% at 68 weeks. Ozempic was studied for glycemic control in the SUSTAIN program, where weight loss was a secondary endpoint and ran roughly 6–8% at the 1.0 mg dose.
Insurance and access
Ozempic is generally covered under diabetes benefits with a prior authorization confirming a type 2 diabetes diagnosis. Wegovy is covered under obesity / weight-management benefits where they exist, which is a far less universal benefit and the leading reason patients cite for paying cash.